Gold compounds as therapeutic agents for human diseases (Q28243207)

The history of gold therapy for tuberculosis

Europe PubMed Central

title

Gold compounds as therapeutic agents for human diseases (English)

0 references

author

Aleksandra Filipovska

series ordinal

2

object named as

Aleksandra Filipovska

0 references

author name string

Susan J Berners-Price

series ordinal

1

0 references

language of work or name

English

0 references

publication date

September 2011

0 references

published in

Metallomics

0 references

volume

3

0 references

issue

9

0 references

page(s)

863-73

0 references

cites work

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

The history of gold therapy in rheumatoid disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Inhibitory effects of a new oral gold compound on hela cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold derivatives for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Anti-cancer potential of gold complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Synthesis, structure and cytotoxicity of triphenylphosphinegold(I) sulfanylpropenoates

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

A gold(I) complex with a vitamin K3 derivative: characterization and antitumoral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Novel gold(I) 7-azacoumarin complex: synthesis, structure, optical properties, and cytotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

A gold(I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Anticancer therapeutics that target selenoenzymes: synthesis, characterization, in vitro cytotoxicity, and thioredoxin reductase inhibition of a series of gold(I) complexes containing hydrophilic phosphine ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

A sugar-modified phosphole gold complex with antiproliferative properties acting as a thioredoxin reductase inhibitor in MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold(I) complex of N,N'-disubstituted cyclic thiourea with in vitro and in vivo anticancer properties-potent tight-binding inhibition of thioredoxin reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Aurothiomalate Inhibits Transformed Growth by Targeting the PB1 Domain of Protein Kinase Cι

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Mitochondrial Membrane Potential in Living Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

In vivo and in vitro cardiotoxicity of a gold-containing antineoplastic drug candidate in the rabbit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold(I) chloride adducts of 1,3-bis(di-2-pyridylphosphino)propane: synthesis, structural studies and antitumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Antitumor activity of the mixed phosphine gold species chlorotriphenylphosphine-1,3-bis(diphenylphosphino)propanegold(I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Mitochondria are primary targets in apoptosis induced by the mixed phosphine gold species chlorotriphenylphosphine-1,3-bis(diphenylphosphino)propanegold(I) in melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Chemical behavior and in vitro activity of mixed phosphine gold(I) compounds on melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

In vitro and in vivo antitumor properties of tetrakis((trishydroxy- methyl)phosphine)gold(I) chloride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Cationic, linear Au(I) N-heterocyclic carbene complexes: synthesis, structure and anti-mitochondrial activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold(III) Porphyrin 1a Induced Apoptosis by Mitochondrial Death Pathways Related to Reactive Oxygen Species

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Proteomic characterization of the cytotoxic mechanism of gold (III) porphyrin 1a, a potential anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Modulation of gold(III) porphyrin 1a-induced apoptosis by mitogen-activated protein kinase signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

A gold(III) porphyrin complex with antitumor properties targets the Wnt/beta-catenin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold(III) porphyrin 1a inhibited nasopharyngeal carcinoma metastasis in vivo and inhibited cell migration and invasion in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold(III) porphyrin 1a prolongs the survival of melanoma-bearing mice and inhibits angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Cyclometalated gold(III) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold-based therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Metal based drugs: from serendipity to design

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Inhibition of lysosomal cysteine proteases by a series of Au(I) complexes: a detailed mechanistic investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Inhibition of cathepsin B by Au(I) complexes: a kinetic and computational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Tuning the Au(I)-mediated inhibition of cathepsin B through ligand substitutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold(I)-mediated inhibition of protein tyrosine phosphatases: a detailed in vitro and cellular study

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Mitochondria as therapeutic targets for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

The thioredoxin system—From science to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Focus on mammalian thioredoxin reductases--important selenoproteins with versatile functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Physiological functions of thioredoxin and thioredoxin reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Interaction of gold(I) with the active site of selenium-glutathione peroxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Substrate and inhibitor specificities differ between human cytosolic and mitochondrial thioredoxin reductases: Implications for development of specific inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Molecular mechanisms of action of gold in treatment of rheumatoid arthritis--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

The Antirheumatic Drug Gold, a Coin With Two Faces: AU(I) and AU(III). Desired and Undesired Effects on the Immune System

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Overexpression of thioredoxin reductase 1 regulates NF‐κB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Induction of cellular antioxidative stress genes through heterodimeric transcription factor Nrf2/small Maf by antirheumatic gold(I) compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

The Escherichia coli copper-responsive copA promoter is activated by gold.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Novel gold(I) phosphine compounds inhibit HIV-1 enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Tetra-chloro-(bis-(3,5-dimethylpyrazolyl)methane)gold(III) chloride: An HIV-1 reverse transcriptase and protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Aurothiolates inhibit HIV-1 infectivity by gold(I) ligand exchange with a component of the virion surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

In vitro inhibition of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase by gold(III) porphyrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Transport of the dicyanogold(i) anion

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Anti-rheumatic compound aurothioglucose inhibits tumor necrosis factor-alpha-induced HIV-1 replication in latently infected OM10.1 and Ach2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Immunomodulatory effect of gold sodium thiomalate on murine acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

HIV therapeutic possibilities of gold compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Inhibition of HIV fusion with multivalent gold nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Metal compounds for the treatment of parasitic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Inhibition of selenium metabolism in the oral pathogen Treponema denticola

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: Results of the METGO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D

Bioinorganic and medicinal chemistry: aspects of gold(i)-protein complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1MT00062D